Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

Purpose: To investigate the therapeutic role of adjuvant vaccination with autologous mature dendritic cells (DC) loaded with tumor lysates derived from autologous, resected glioblastoma multiforme (GBM) at time of relapse. Experimental Design: Fifty-six patients with relapsed GBM (WHO grade IV) were treated with at least three vaccinations. Children and adults were treated similarly in three consecutive cohorts, with progressively shorter vaccination intervals per cohort. Feasibility and toxicity were assessed as well as effect of age, extent of resection, Karnofsky Performance Score, and treatment cohort on the progression-free (PFS) and overall survival (OS) using univariable and multivariable analysis. Results: Since the prevaccine reoperation, the median PFS and OS of the total group was 3 and 9.6 months, respectively, with a 2-year OS of 14.8%. Total resection was a predictor for better PFS both in univariable analysis and after correction for the other covariates. For OS, younger age and total resection were predictors of a better outcome in univariable analysis but not in multivariable analysis. A trend to improved PFS was observed in favor of the faster DC vaccination schedule with tumor lysate boosting. Vaccine-related edema in one patient with gross residual disease before vaccination was the only serious adverse event. Conclusion: Adjuvant DC-based immunotherapy for patients with relapsed GBM is safe and can induce long-term survival. A trend to PFS improvement was shown in the faster vaccination schedule. The importance of age and a minimal residual disease status at the start of the vaccination is underscored.

[1]  G. Bartsch,et al.  Antigen-independent immune responses after dendritic cell vaccination , 2007, Cancer Immunology, Immunotherapy.

[2]  J. Ceuppens,et al.  Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells , 2007, Journal of Neuro-Oncology.

[3]  Michael Sabel,et al.  DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS: CURRENT STATUS AND FUTURE DIRECTIONS , 2006, Neurosurgery.

[4]  R. Toes,et al.  Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. , 2006, Immunobiology.

[5]  Stefan Rutkowski,et al.  Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. , 2006, Anticancer research.

[6]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[7]  J. Blay,et al.  Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model , 2006, Cancer Immunology, Immunotherapy.

[8]  R. Yamanaka.  Novel immunotherapeutic approaches to glioma. , 2006, Current opinion in molecular therapeutics (Print).

[9]  Christian W. Sikorski,et al.  Immunotherapy for malignant glioma: current approaches and future directions , 2005, Neurological research.

[10]  G. Prendergast,et al.  Marrying immunotherapy with chemotherapy: why say IDO? , 2005, Cancer research.

[11]  K. Black,et al.  Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy , 2005, Oncogene.

[12]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[13]  D. Andrews,et al.  Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells , 2005, Clinical Cancer Research.

[14]  K. Black,et al.  Dendritic cell-based immunotherapy for malignant gliomas , 2005, Expert review of neurotherapeutics.

[15]  Naoto Tsuchiya,et al.  Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  G. Finocchiaro,et al.  Cell therapies in neuro-oncology , 2005, Neurological Sciences.

[17]  J. Ceuppens,et al.  Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells , 2005, Cancer Immunology, Immunotherapy.

[18]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[19]  K. Black,et al.  Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients. , 2005, Current opinion in molecular therapeutics.

[20]  P. Flamen,et al.  Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study , 2004, British Journal of Cancer.

[21]  E. Thiel,et al.  Immunological monitoring of cancer vaccine therapy , 2004, Expert opinion on biological therapy.

[22]  Keith L Black,et al.  Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.

[23]  Keith L Black,et al.  Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[24]  R. Sciot,et al.  Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. , 2004, Journal of neurosurgery.

[25]  W. Lehmacher,et al.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial , 2004, The Lancet.

[26]  S. Grossman.  Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas. , 2003, Seminars in oncology.

[27]  D. Bigner,et al.  The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors , 2003, Journal of Neuro-Oncology.

[28]  A. Nowak,et al.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. , 2003, Cancer research.

[29]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[30]  H. Okada,et al.  Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells , 2001, Gene Therapy.

[31]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M Molls,et al.  A comparison of treatment results for recurrent malignant gliomas. , 2000, Cancer treatment reviews.

[33]  T. Whiteside.  Immunologic Monitoring of Clinical Trials in Patients with Cancer: Technology Versus Common Sense , 2000, Immunological investigations.

[34]  T. Roszman,et al.  Immune defects observed in patients with primary malignant brain tumors , 1999, Journal of Neuroimmunology.

[35]  D. Kondziolka,et al.  Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. , 1999, Neurosurgery.

[36]  M. Prados,et al.  Survival and functional status after resection of recurrent glioblastoma multiforme. , 1998, Neurosurgery.

[37]  A. Brandes,et al.  Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas , 1997 .

[38]  J. Wolff,et al.  HIT-GBM: MULTIZENTRISCHE STUDIE ZUR BEHANDLUNG VON KINDERN MIT MALIGNEN GLIOMEN , 1996 .

[39]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[40]  T. Roszman,et al.  Modulation of T-cell function by gliomas. , 1991, Immunology today.

[41]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  N. Bleehen,et al.  A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. , 1989, International journal of radiation oncology, biology, physics.

[43]  T. Roszman,et al.  Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. , 1987, Journal of neurosurgery.

[44]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[45]  H. Oberg,et al.  Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. , 2006, Critical reviews in immunology.

[46]  F. Calenbergh,et al.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells , 2004, Child's Nervous System.

[47]  J. Wolff,et al.  [HIT-GBM: multicenter study of treatment of children with malignant glioma]. , 1996, Klinische Padiatrie.

[48]  S. Bertolone,et al.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.